Function‐Oriented Natural Product Synthesis-Reference-Cited by-同舟云学术

Function‐Oriented Natural Product Synthesis

Published:2021-03-29 Issue:4 Volume:39 Page:838-854
ISSN:1001-604X
Container-title:Chinese Journal of Chemistry
language:en
Short-container-title:Chin. J. Chem.

Author:

Chen Kaiqi¹,Wu Fan¹,Lei Xiaoguang¹²

Affiliation:

1. Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Department of Chemical Biology, College of Chemistry and Molecular Engineering, Synthetic and Functional Biomolecules Center, Peking University Beijing 100871 China

2. Peking‐Tsinghua Center for Life Science, Academy for Advanced Interdisciplinary Studies, Peking University Beijing 100871 China

Publisher

Wiley

Subject

General Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cjoc.202000509

Reference51 articles.

1. Natural Products as Sources of New Drugs from 1981 to 2014

2. The evolving role of natural products in drug discovery

3. Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack

4. Target identification for biologically active small molecules using chemical biology approaches

5. Ainsliadimer A, A New Sesquiterpene Lactone Dimer with an Unusual Carbon Skeleton from Ainsliaea macrocephala

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of (+)-epicolidine C and the 6/6/6/5 tetracyclic core of spylidone;Tetrahedron Letters;2024-08

2. Chemoenzymatic total synthesis of alchivemycin A;Nature Synthesis;2024-06-25

3. Green Oxidation of Isochromans to Isochromanones with Molecular Oxygen Catalyzed by a Tetranuclear Vanadium Cluster;Chinese Journal of Chemistry;2023-05-09

4. Divergent total syntheses of ITHQ-type bis-β-carboline alkaloids by regio-selective formal aza-[4 + 2] cycloaddition and late-stage C–H functionalization;Chemical Science;2023

5. Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression;Pharmacological Research;2023-01